Adverum Biotechnologies, Inc.
ADVMDelisted Dec 9, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501756
Adverum Biotechnologies, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 10, 2025; 50 institutions reported holding it in 13F filings for Q3 2025, worth $63.8M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Adverum Biotechnologies, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Adverum Biotechnologies, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Whitcup Scott M | Director | – | Dec 10, 2025 | 1 |
| Machado Patrick | Director | 0 | Dec 10, 2025 | 1 |
| Rubinstein Linda M | CHIEF FINANCIAL OFFICER | 0 | Dec 10, 2025 | 1 |
| Scopa James Paul | Director | 0 | Dec 10, 2025 | 1 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | 0 | Dec 10, 2025 | 2 |
| Tuckson Reed Vaughn | Director | – | Dec 10, 2025 | 1 |
| Svoronos Dawn | Director | 0 | Dec 10, 2025 | 1 |
| Nicholson, C. David | Director | – | Dec 10, 2025 | 1 |
| Soparkar Peter | CHIEF OPERATING OFFICER | 0 | Dec 10, 2025 | 2 |
| Lupher, Jr. Mark L. | Director | 0 | Dec 10, 2025 | 1 |
| Ozden Rabia Gurses | Chief Medical Officer | 0 | Dec 10, 2025 | 1 |
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | 0 | Dec 10, 2025 | 1 |
| Hong Soo | Director | – | Dec 10, 2025 | 1 |
| Kiss Szilard | Director | – | Dec 10, 2025 | 1 |
| Frazier Life Sciences Public Fund, L.P. | 10% Owner | 0 | Dec 9, 2025 | 1 |
| FHMLSP, L.L.C. | 10% Owner | 0 | Dec 9, 2025 | 1 |
| FHMLSP, L.P. | 10% Owner | 0 | Dec 9, 2025 | 1 |
| Leonard Braden Michael | 10% Owner | 1,958,080Indirect | Dec 5, 2025 | 2 |
| Riley Brigit | Chief Scientific Officer | 117,435 | Mar 17, 2023 | 0 |
| Beckman Richard | Chief Medical Officer | 39,061 | Mar 3, 2023 | 0 |
| Rakow John | SVP, Genl Counsel, Acting CFO | – | Sep 16, 2022 | 0 |
| D'Souza Rupert | Chief Financial Officer | 20,850 | May 17, 2022 | 0 |
| Clark Julie | Chief Medical Officer | 164,723 | Oct 4, 2021 | 0 |
| Thedinga Angela | Chief Technology Officer | 150,000 | Aug 10, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 (view filing) | Dec 5 | 3 days | Soparkar PeterCHIEF OPERATING OFFICER | PPurchase | +50.0K | $4.22 | +$211.0K | +165.6%80.2K after | |
| Dec 8, 2025 (view filing) | Dec 5-8 | 3 days | Fischer LaurentCEO, PRESIDENT AND DIRECTOR | PPurchase | +128.7K | $4.30 | +$553.9K | +176.8%201.5K after | 2 lots |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Leonard Braden Michael10% Owner | SSale | −524.6K | $4.19 | −$2.20M | −21.1%1.96M after | |
| Dec 3, 2025 (view filing) | Dec 1-3 | 2 days | Leonard Braden Michael10% Owner | SSale | −574.9K | $4.19 | −$2.41M | −19.1%2.43M after | 3 lots |
| May 16, 2025 (view filing) | May 15 | 1 day | Soparkar PeterCHIEF OPERATING OFFICER | SSale | −2.96K | $2.00 | −$5.92K | −7.0%39.2K after | |
| May 16, 2025 (view filing) | May 15 | 1 day | Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER | SSale | −924 | $2.00 | −$1.85K | −6.3%13.8K after | |
| May 16, 2025 (view filing) | May 15 | 1 day | Fischer LaurentCEO, PRESIDENT AND DIRECTOR | SSale | −9.13K | $2.00 | −$18.3K | −9.4%87.5K after | |
| Apr 28, 2025 (view filing) | Mar 26-27 | 33 days | Leonard Braden Michael10% Owner | PPurchase | +37.0K | $5.11 | +$189.0K | +35.3%141.8K after | Amended2 lotsDuplicate filing |
| Apr 28, 2025 (view filing) | Mar 26-27 | 33 daysLate | Leonard Braden Michael10% Owner | PPurchase | +37.0K | $5.11 | +$189.0K | +35.3%141.8K after | 2 lots |
| Apr 24, 2025 (view filing) | Apr 22 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +300.0K | $3.00 | +$900.0K | +10.9%3.06M after | |
| Apr 24, 2025 (view filing) | Apr 23 | 1 day | Leonard Braden Michael10% Owner | PPurchase | +50.0K | $2.98 | +$149.0K | +35.3%191.8K after | |
| Apr 2, 2025 (view filing) | Mar 31-Apr 2 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +34.8K | $4.23 | +$147.1K | +1.3%2.76M after | 2 lots |
| Mar 20, 2025 (view filing) | Mar 18-19 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +87.3K | $4.76 | +$416.0K | +3.4%2.69M after | 3 lots |
| Mar 20, 2025 (view filing) | Mar 20 | Same day | Leonard Braden Michael10% Owner | PPurchaseCommon Stovk | +30.6K | $5.61 | +$171.7K | +1.1%2.72M after | |
| Feb 28, 2025 (view filing) | Feb 26-28 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +336.8K | $4.28 | +$1.44M | +14.8%2.60M after | 3 lots |
| Jul 31, 2024 (view filing) | Jul 30 | 1 day | Leonard Braden Michael10% Owner | PPurchase | +85.8K | $7.15 | +$613.5K | +3.9%2.27M after | |
| Jul 18, 2024 (view filing) | Jul 17-18 | 1 day | Leonard Braden Michael10% Owner | PPurchase | +216.3K | $8.26 | +$1.79M | +11.0%2.18M after | 2 lots |
| Feb 9, 2024 (view filing) | Feb 7 | 2 days | Scopa James PaulDirector | PPurchase | +100.0K | $1.35 | +$135.0K | New position100.0K after | |
| Feb 9, 2024 (view filing) | Feb 7 | 2 days | Lupher, Jr. Mark L.Director | PPurchase | +130.0K | $1.35 | +$175.5K | New position130.0K after | |
| Sep 18, 2023 (view filing) | Sep 15 | 3 days | Seyedkazemi SetarehChief Development Officer | SSale | −6.20K | $1.52 | −$9.43K | −11.5%47.7K after | 2 lots |
| Jun 9, 2023 (view filing) | Jun 7 | 2 days | Rubinstein Linda MChief Financial Officer | PPurchase | +100.0K | $1.45 | +$145.0K | New position100.0K after | |
| Mar 17, 2023 (view filing) | Mar 15 | 2 days | Riley BrigitChief Scientific Officer | SSale | −7.30K | $0.78 | −$5.69K | −5.9%117.4K after | |
| Mar 17, 2023 (view filing) | Mar 15 | 2 days | Soparkar PeterChief Operating Officer | SSale | −13.4K | $0.78 | −$10.4K | −4.8%265.9K after | |
| Mar 17, 2023 (view filing) | Mar 15 | 2 days | Fischer LaurentCEO, President and Director | SSale | −41.2K | $0.78 | −$32.2K | −5.6%692.1K after | |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Beckman RichardChief Medical Officer | SSale | −4.27K | $1.07 | −$4.57K | −9.9%39.1K after | |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Seyedkazemi SetarehChief Development Officer | SSale | −6.06K | $1.07 | −$6.48K | −11.2%47.9K after | |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Soparkar PeterSee Remarks section | SSale | −13.3K | $1.07 | −$14.2K | −4.6%273.3K after | |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Riley BrigitChief Scientific Officer | SSale | −7.27K | $1.07 | −$7.77K | −5.8%118.7K after | |
| Sep 21, 2022 (view filing) | Sep 19 | 2 days | Fischer LaurentCEO, President and Director | SSale | −41.1K | $1.07 | −$44.0K | −5.3%727.4K after | |
| May 24, 2022 (view filing) | May 23 | 1 day | Seyedkazemi SetarehChief Development Officer | PPurchase | +20.0K | $0.84 | +$16.8K | +3,333.3%20.6K after | |
| May 19, 2022 (view filing) | May 17 | 2 days | Beckman RichardChief Medical Officer | PPurchase | +10.0K | $0.82 | +$8.20K | New position10.0K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Svoronos DawnDirector | PPurchase | +30.0K | $0.85 | +$25.5K | +150.0%50.0K after | |
| May 17, 2022 (view filing) | May 13-17 | 4 days | D'Souza RupertChief Financial Officer | PPurchase | +20.0K | $0.845 | +$16.9K | +2,352.9%20.9K after | 2 lots |
| Apr 22, 2022 (view filing) | Apr 20 | 2 days | Fischer LaurentCEO, President and Director | PPurchase | +25.0K | $1.11 | +$27.8K | +3.4%762.5K after | |
| Apr 20, 2022 (view filing) | Apr 19 | 1 day | Soparkar PeterSee Remarks section | PPurchase | +21.9K | $1.14 | +$25.0K | +8.5%280.6K after | 2 lots |
| Dec 10, 2021 (view filing) | Dec 8-9 | 2 days | Fischer LaurentCEO, President and Director | PPurchase | +25.0K | $1.82 | +$45.6K | +3.5%737.5K after | 2 lots |
| Dec 10, 2021 (view filing) | Dec 8 | 2 days | Soparkar PeterSee Remarks section | PPurchase | +25.0K | $1.91 | +$47.8K | +10.7%258.6K after | |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Scopa James PaulDirector | SSale | −50.0K | $2.18 | −$109.0K | −93.7%3.33K after | |
| Oct 4, 2021 (view filing) | Sep 30 | 4 days | Clark JulieChief Medical Officer | SSale | −4.77K | $2.17 | −$10.3K | −2.8%164.7K after |